JD Vance Predicts: Wall Street vs. Trump & Your Money

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Michael Secora Biography and Net Worth

CFO of Recursion Pharmaceuticals

Michael Secora, Ph.D., has served as our Chief Financial Officer since March 2020. Prior to joining us, Dr. Secora worked at Laurion Capital Management, as an asset manager based in New York City from July 2010 to February 2020, where he was Managing Director and Head of Capital Markets and Venture. During his time at Laurion, he developed, executed and managed fundamentally grounded investment strategies as well as built business partnerships and technological infrastructure for investing in event-driven, fundamental and macroeconomic contexts.

At Laurion Capital Management, Dr. Secora was active in venture, crossover, capital markets, public and special situations investing particularly within emerging technologies and the life sciences. Dr. Secora received his Ph.D. from Princeton University in Applied and Computational Mathematics and B.S. in Mathematics and Physics from Massachusetts Institute of Technology.

What is Michael Secora's net worth?: The estimated net worth of Michael Secora is at least $9.06 million as of November 13th, 2024. Dr. Secora owns 1,499,631 shares of Recursion Pharmaceuticals stock worth more than $9,057,771 as of November 20th. This net worth evaluation does not reflect any other assets that Dr. Secora may own. Additionally, Dr. Secora receives a salary of $629,780.00 as CFO at Recursion Pharmaceuticals. Learn More about Michael Secora's net worth.
How old is Michael Secora?: Dr. Secora is currently 41 years old. There are 3 older executives and no younger executives at Recursion Pharmaceuticals. The oldest executive at Recursion Pharmaceuticals is Dr. David J. Mauro M.D., Ph.D., Chief Medical Officer, who is 59 years old. Learn More on Michael Secora's age.
What is Michael Secora's salary?: As the CFO of Recursion Pharmaceuticals, Inc., Dr. Secora earns $629,780.00 per year. There are 3 executives that earn more than Dr. Secora. The highest earning executive at Recursion Pharmaceuticals is Dr. Christopher C. Gibson Ph.D., Co-Founder, CEO & Director, who commands a salary of $806,720.00 per year. Learn More on Michael Secora's salary.
How do I contact Michael Secora?: The corporate mailing address for Dr. Secora and other Recursion Pharmaceuticals executives is 41S RIO GRANDE STREET, SALT LAKE CITY UT, 84101. Recursion Pharmaceuticals can also be reached via phone at 385-269-0203 and via email at [email protected]. Learn More on Michael Secora's contact information.
Has Michael Secora been buying or selling shares of Recursion Pharmaceuticals?: During the last ninety days, Michael Secora has sold $209,700.00 of Recursion Pharmaceuticals stock. Most recently, Michael Secora sold 15,000 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a transaction totalling $114,900.00. Following the completion of the sale, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at $11,487,173.46. Learn More on Michael Secora's trading history.
Who are Recursion Pharmaceuticals' active insiders?: Recursion Pharmaceuticals' insider roster includes Blake Borgeson (Director), Terry-Ann Burrell (Director), Zavain Dar (Director), Christopher Gibson (CEO), Tina Larson (COO), Dean Li (Director), Michael Secora (CFO), and Shafique Virani (Chief Corporate Development Officer). Learn More on Recursion Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Recursion Pharmaceuticals?: In the last year, insiders at the sold shares 61 times. They sold a total of 1,151,301 shares worth more than $10,096,309.56. The most recent insider tranaction occured on November, 13th when CFO Michael Secora sold 15,000 shares worth more than $114,900.00. Insiders at Recursion Pharmaceuticals own 15.8% of the company. Learn More about insider trades at Recursion Pharmaceuticals.
Information on this page was last updated on 11/13/2024.

Michael Secora Insider Trading History at Recursion Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/13/2024	Sell	15,000	$7.66	$114,900.00	1,499,631
10/8/2024	Sell	15,000	$6.32	$94,800.00	1,426,506
9/10/2024	Sell	15,000	$6.17	$92,550.00	1,377,756
8/13/2024	Sell	15,000	$6.35	$95,250.00	1,340,968
7/9/2024	Sell	15,000	$7.32	$109,800.00	1,292,218
6/13/2024	Sell	15,000	$9.32	$139,800.00	1,243,468
4/17/2024	Sell	23,124	$7.58	$175,279.92	1,231,055
3/13/2024	Sell	25,000	$11.03	$275,750.00	1,204,179
2/13/2024	Sell	25,000	$9.86	$246,500.00	1,173,851
1/16/2024	Sell	25,000	$10.45	$261,250.00	968,514
12/12/2023	Sell	25,000	$7.39	$184,750.00	943,514
11/14/2023	Sell	25,000	$6.32	$158,000.00	925,686
10/10/2023	Sell	25,000	$7.07	$176,750.00	900,686
9/13/2023	Sell	25,000	$8.69	$217,250.00	888,186
8/16/2023	Sell	25,000	$8.90	$222,500.00	863,186
7/18/2023	Sell	25,000	$13.63	$340,750.00	830,413
6/13/2023	Sell	25,000	$9.93	$248,250.00	805,413

Michael Secora Buying and Selling Activity at Recursion Pharmaceuticals

Recursion Pharmaceuticals Company Overview

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Today's Range

Now: $6.04

$5.70

$6.37

50 Day Range

MA: $6.65

$6.04

$7.84

2 Week Range

Now: $6.04

$5.70

$15.74

Volume

16,994,717 shs

Average Volume

6,194,816 shs

Market Capitalization

$1.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81

JD Vance Predicts: Wall Street vs. Trump & Your Money

From Priority Gold | Ad

Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.

Get your free guide NOW before it's too late.

Michael Secora Biography and Net Worth

What is Michael Secora's net worth?

How old is Michael Secora?

What is Michael Secora's salary?

How do I contact Michael Secora?

Has Michael Secora been buying or selling shares of Recursion Pharmaceuticals?

Who are Recursion Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Recursion Pharmaceuticals?